



## **Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026**

April 15, 2026

DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter 2026 financial results and conduct a conference call on Wednesday, April 29, 2026. The Company will issue a press release detailing its first quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET.

Information on how to participate is as follows.

### Access to the live call:

Via telephone: Dial in within the United States: 888-506-0062

International dial in: 973-528-0011

Access Code: 543818

Via online: A webcast of the call will be available on the Investor Relations section of the Company's website at [www.amarincorp.com](http://www.amarincorp.com).

### Access to the replay:

Via telephone: Dial in within the United States: 877-481-4010

International dial in: 919-882-2331

Replay Code: 53836

Via online: A replay of the webcast will be accessible through the Investor Relations section of the Company's website at [www.amarincorp.com](http://www.amarincorp.com), beginning shortly after the end of the live call and available until 10/29/26.

### **About Amarin**

Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally, through a syndicate of reputable and well-established partners with significant geographic expertise, covering close to 100 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world's leading cause of death, CVD.

### **Availability of Other Information About Amarin**

Amarin communicates with its investors and the public using the company website ([www.amarincorp.com](http://www.amarincorp.com)) and the investor relations website (<http://www.amarincorp.com/investor-relations>), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin's investor relations website and may include social media channels. The contents of Amarin's website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

### **Amarin Contact Information**

Media Inquiries:

Tegan Berry

Amarin Corporation plc

[PR@amarincorp.com](mailto:PR@amarincorp.com)

Investor Inquiries:

Devin Sullivan & Conor Rodriguez

The Equity Group on Behalf of Amarin

[dsullivan@theequitygroup.com](mailto:dsullivan@theequitygroup.com) or [crodriguez@theequitygroup.com](mailto:crodriguez@theequitygroup.com)

[Investor.relations@amarincorp.com](mailto:Investor.relations@amarincorp.com)

